TD Cowen analyst Ritu Baral maintained a Buy rating on Neurogene (NGNE – Research Report) today. The company’s shares closed yesterday at ...

DeepSeek has quickly gained attention in AI with its R1 model, which delivers high performance at a lower cost.

TD Cowen analyst Bryan Bergin upgraded Genpact (G) to Buy from Hold with a price target of $60, up from $45. The company’s turnaround traction ...

TD Cowen reaffirmed their buy rating on shares of Tempus AI (NASDAQ:TEM – Free Report) in a research note published on Wednesday, Marketbeat Ratings reports. TD Cowen currently has a $74.00 price ...

As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scala asked CEO David Ricks if the company ...

Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry Genetics ...

Investing.com -- TD Cowen reinstated coverage on Tempus AI with a "Buy" rating and raised its price target to $74 after the health-tech company completed its $600 million acquisition of Ambry ...

Traditional media companies that have launched stand-alone streaming services should pivot hard, TD Cowen analysts argued in a recent report. The analysts say Warner Bros. Discovery, Disney ...

As the global AI race heated up last month with the launch of DeepSeek R1 and Alibaba’s Qwen 2.5 AI models, US AI firms are ...

TD Cowen began coverage on shares of Palvella Therapeutics (NASDAQ:PVLA – Free Report) in a research report released on Wednesday morning, MarketBeat.com reports. The firm issued a buy rating and a ...